CDKN2A and hepatocellular carcinoma: The four sarcomatoid HCC patients with CDKN2A mutation suffered HCC recurrence with a median time of 2.4 months after surgery and had significantly lower survival as compared to the other 11 sarcomatoid HCC patients without CDKN2A mutation (Figure S3).